May 10, 2023
Eisai said on May 9 that it has downwardly revised its revenue and profit forecast for the year that ended March 2023 owing to a foreign exchange headwind and the underperformance of core products Lenvima (lenvatinib) and Fycompa (perampanel) in...read more